Nature Reviews Drug Discovery contents January 2018 Volume 17 Number 1 pp 1-78

If you are unable to see the message below, click here to view.
 

Advertisement
Nature Reviews Disease Primers — Stay updated  Nature Reviews Disease Primers covers all medical specialties, already having published on more than 120 diseases and disorders since launching in 2015. With such a comprehensive article collection, our e-alerts are the perfect solution to stay updated on the latest content published by the journal.  Register for the e-alert
TABLE OF CONTENTS
January 2018 Volume 17 Number 1
2016 2-year Impact Factor 57.000 Journal Metrics 2-year Median 38	In this issue Comment News and Analysis Research Highlights Analysis Reviews   Also this month  Featured article: Host-directed therapies for bacterial and viral infections Stefan H. E. Kaufmann, Anca Dorhoi, Richard S. Hotchkiss & Ralf Bartenschlager
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Comment: Steps forward for cancer precision medicine Roberto Salgado, Helen Moore, John W. M. Martens, Tracy Lively, Shakun Malik, Ultan McDermott, Stefan Michiels, Jeffrey A. Moscow, Sabine Tejpar, Tawnya McKee, Denis Lacombe & on behalf of the IBCD-Faculty p1 | doi:10.1038/nrd.2017.218 The availability of targeted anticancer drugs and the relative affordability of genomic analyses has led to a growing expectation among patients with cancer that they can receive personalized treatment based on the genomic signature of their tumour. Here, we discuss some of the challenges and steps needed to bring such approaches into routine practice. Abstract | Full Text | PDF | Supplementary information
NEWS AND ANALYSIS		Top
Can innate immune system targets turn up the heat on 'cold' tumours? Asher Mullard p3 | doi:10.1038/nrd.2017.264 STING, RIG-I and NLRP3 agonists might increase the effectiveness of immuno-oncology checkpoint inhibitors, while antagonists of these targets offer an anti-inflammatory bonus. PDF
NEWS IN BRIEF First in vivo gene-editing drugs enter the clinic Asher Mullard p7 | doi:10.1038/nrd.2017.268 PDF
Boehringer Ingelheim experiments with open-access chemical probes Asher Mullard p7 | doi:10.1038/nrd.2017.269 PDF
Sage gets an antidepressant lift Asher Mullard p7 | doi:10.1038/nrd.2017.270 PDF
BIOBUSINESS BRIEFS Deal watch: Roche taps potential antibiotics mine with Warp Drive Bio Megan Cully p8 | doi:10.1038/nrd.2017.247 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q1 2018 Tanner Collins p8 | doi:10.1038/nrd.2017.263 PDF
AN AUDIENCE WITH Sean Harper p10 | doi:10.1038/nrd.2017.262 Sean Harper, Amgen's Chief Scientific Officer, talks about how human genetic data can be used to avoid costly failures, prosecute programmes more effectively and discover de novo drug targets. PDF
FROM THE ANALYST'S COUCH Biomarker strategy in lung cancer Mine Esencay, Andrew Watson, Kaushiki Mukherjee, Delphine Hanicq & Steven I. Gubernick p13 | doi:10.1038/nrd.2017.166 This article discsusses how biomarkers will continue to change the market for non-small-cell lung cancer. PDF
RESEARCH HIGHLIGHTS   Top Cancer: Strategies for mature T cell cancers p15 | doi:10.1038/nrd.2017.254 PDF Cancer immunotherapy: Microbes matter p16 | doi:10.1038/nrd.2017.265 PDF Infectious disease: Blocking malaria parasite invasion and egress p17 | doi:10.1038/nrd.2017.253 PDF Cancer Immunotherapy: The right shape p18 | doi:10.1038/nrd.2017.256 PDF   IN BRIEF Cancer: Targeting telomeres | Immunotherapy: Vaccine patch to treat melanoma | Technology: New method for endogenous protein degradation | Cancer: Inhibiting DNA damage signalling PDF
ANALYSIS		Top
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications Hsin-Pei Shih, Xiaodan Zhang & Alex M. Aronov p19 | doi:10.1038/nrd.2017.194 Shih and colleagues analyse comprehensive industry-wide data on drug development projects pursued during the past 20 years, classified according to the mechanism and indication for each project. Their findings indicate several points and trends that may be useful in understanding and improving the productivity of the pharmaceutical industry, including areas with substantial success or failure and the relative extent of novelty in completed and ongoing projects. Abstract | Full Text | PDF | Supplementary information
REVIEWS		Top
Host-directed therapies for bacterial and viral infections Stefan H. E. Kaufmann, Anca Dorhoi, Richard S. Hotchkiss & Ralf Bartenschlager p35 | doi:10.1038/nrd.2017.162 Host-directed therapy (HDT) aims to interfere with host cell factors that are required by a pathogen for replication or persistence. In this Review, Kaufmann et al. describe recent progress in the development of HDTs for the treatment of viral and bacterial infections and the challenges in bringing these approaches to the clinic. Abstract | Full Text | PDF | Supplementary information
Deubiquitylating enzymes and drug discovery: emerging opportunities Jeanine A. Harrigan, Xavier Jacq, Niall M. Martin & Stephen P. Jackson p57 | doi:10.1038/nrd.2017.152 Deubiquitylating enzymes (DUBs) have been implicated in several human diseases, including cancer, neurodegenerative diseases, inflammatory and autoimmune disorders, as well as infectious diseases. Here, Jackson and colleagues discuss the pathological roles of DUBs, consider the challenges in the development of selective DUB inhibitors and highlight first-generation agents approaching clinical trials. Abstract | Full Text | PDF
Corrigendum: Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications Hsin-Pei Shih, Xiaodan Zhang & Alex M. Aronov p78 | doi:10.1038/nrd.2017.255 Full Text | PDF
Erratum: Mechanistic enzymology in drug discovery: a fresh perspective Geoffrey A. Holdgate, Thomas D. Meek & Rachel L. Grimley p78 | doi:10.1038/nrd.2017.257 Full Text | PDF
Corrigendum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases Daniella M. Schwartz, Yuka Kanno, Alejandro Villarino, Michael Ward, Massimo Gadina & John J. O'Shea p78 | doi:10.1038/nrd.2017.267 Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.